View all text of Subjgrp 103 [§ 4.88 - § 4.89]
§ 4.88b - Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.
Note:
[61 FR 39875, July 31, 1996, as amended at 84 FR 28230, June 18, 2019]
Rate any residual disability of infection within the appropriate body system as indicated by the notes in the evaluation criteria. As applicable, consider the long-term health effects potentially associated with infectious diseases as listed in § 3.317(d) of this chapter, specifically Brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), Malaria, Mycobacterium Tuberculosis, Nontyphoid Salmonella, Shigella, Visceral Leishmaniasis, and West Nile virus.
Rating | For active disease | 100 | After active disease has resolved, rate at 0 percent for infection. Rate any residual disability of infection within the appropriate body system. | 6300 Vibriosis (Cholera, Non-cholera): | Evaluate under the General Rating Formula. | 6301 Visceral leishmaniasis: | As active disease | 100 | 6302 Leprosy (Hansen's disease): | As active disease | 100 | 6304 Malaria: | Evaluate under the General Rating Formula. | 6305 Lymphatic filariasis, to include elephantiasis: | Evaluate under the General Rating Formula. | 6306 Bartonellosis: | Evaluate under the General Rating Formula. | 6307 Plague: | Evaluate under the General Rating Formula. | 6308 Relapsing Fever: | Evaluate under the General Rating Formula. | 6309 Rheumatic fever: | Evaluate under the General Rating Formula. | 6310 Syphilis, and other treponema infections: | 6311 Tuberculosis, miliary: | As active disease | 100 | Inactive disease: | 6312 Nontuberculosis mycobacterium infection: | As active disease | 100 | 6313 Avitaminosis: | Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia | 100 | With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor | 60 | With stomatitis, diarrhea, and symmetrical dermatitis | 40 | With stomatitis, or achlorhydria, or diarrhea | 20 | Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability | 10 | 6314 Beriberi: | As active disease: | With congestive heart failure, anasarca, or Wernicke-Korsakoff syndrome | 100 | With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles | 60 | With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep disturbance | 30 | Thereafter rate residuals under the appropriate body system. | 6315 Pellagra: | Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia | 100 | With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor | 60 | With stomatitis, diarrhea, and symmetrical dermatitis | 40 | With stomatitis, or achlorhydria, or diarrhea | 20 | Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability | 10 | 6316 Brucellosis: | Evaluate under the General Rating Formula. | 6317 Rickettsial, ehrlichia, and anaplasma infections: | Evaluate under the General Rating Formula. | 6318 Melioidosis: | Evaluate under the General Rating Formula. | 6319 Lyme disease: | Evaluate under the General Rating Formula. | 6320 Parasitic diseases otherwise not specified: | Evaluate under the General Rating Formula. | 6325 Hyperinfection syndrome or disseminated strongyloidiasis: | As active disease | 100 | 6326 Schistosomiasis: | As acute or asymptomatic chronic disease | 0 | 6329 Hemorrhagic fevers, including dengue, yellow fever, and others: | Evaluate under the General Rating Formula. | 6330 Campylobacter jejuni infection: | Evaluate under the General Rating Formula. | 6331 Coxiella burnetii infection (Q fever): | Evaluate under the General Rating Formula. | 6333 Nontyphoid salmonella infections: | Evaluate under the General Rating Formula. | 6334 Shigella infections: | Evaluate under the General Rating Formula. | 6335 West Nile virus infection: | Evaluate under the General Rating Formula. | 6350 Lupus erythematosus, systemic (disseminated): | Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe impairment of health | 100 | Exacerbations lasting a week or more, 2 or 3 times per year | 60 | Exacerbations once or twice a year or symptomatic during the past 2 years | 10 | 6351 HIV-related illness: | AIDS with recurrent opportunistic infections (see Note 3) or with secondary diseases afflicting multiple body systems; HIV-related illness with debility and progressive weight loss | 100 | Refractory constitutional symptoms, diarrhea, and pathological weight loss; or minimum rating following development of AIDS-related opportunistic infection or neoplasm | 60 | Recurrent constitutional symptoms, intermittent diarrhea, and use of approved medication(s); or minimum rating with T4 cell count less than 200 | 30 | Following development of HIV-related constitutional symptoms; T4 cell count between 200 and 500; use of approved medication(s); or with evidence of depression or memory loss with employment limitations | 10 | Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count | 0 | 6354 Chronic fatigue syndrome (CFS): | Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, or confusion), or a combination of other signs and symptoms: | Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care | 100 | Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year | 60 | Which are nearly constant and restrict routine daily activities from 50 to 75 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year | 40 | Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total duration per year | 20 | Which wax and wane but result in periods of incapacitation of at least one but less than two weeks total duration per year; or symptoms controlled by continuous medication | 10 |
---|